Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range

Transplantation

Volumn 73, Issue 6, 2002, Pages 920-925

  Kovarik, John M ^a   Kaplan, Bruce ^a   Silva, Hélio Tedesco ^a   Kahan, Barry D ^a   Dantal, Jacque ^a   Vitko, Stefan ^a   Boger, Robert ^a   Rordorf, Christiane ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037181426     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200203270-00016     Document Type: Article

References (13)

1. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo
2. Rapamune (sirolimus, rapamycin): An overview and mechanism of action
3. Phase I study of a 4-week course of RAD in quiescent cyclosporine-prednisone-treated renal transplant recipients
4. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection
5. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
6. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine
7. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
8. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
9. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
10. Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients
11. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
12. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
13. Immunosuppression enhances atherogenicity of lipid profile after transplantation